Identification

Name
Acarbose
Accession Number
DB00284  (APRD00656)
Type
Small Molecule
Groups
Approved, Investigational
Description

An inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed)

Structure
Thumb
Synonyms
  • Acarbosa
  • Acarbose
  • Acarbosum
External IDs
Bay g 5421 / BAY-g 5421 / BAY-G-5421 / BAYG5421 / HSDB 7984
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GlucobayTablet50 mgOralBayer1996-02-02Not applicableCanada
GlucobayTablet100 mgOralBayer1996-02-02Not applicableCanada
PrecoseTablet50 mg/1OralBayer Pharmaceuticals Corporation2006-03-312006-03-31Us
PrecoseTablet25 mg/1OralBayer HealthCare Pharmaceuticals Inc.2008-01-30Not applicableUs
PrecoseTablet25 mg/1OralPhysicians Total Care, Inc.2007-11-19Not applicableUs
PrecoseTablet100 mg/1OralBayer HealthCare Pharmaceuticals Inc.2008-01-30Not applicableUs
PrecoseTablet50 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-01-30Not applicableUs
PrecoseTablet100 mg/1OralBayer Pharmaceuticals Corporation2006-03-312006-03-31Us
PrecoseTablet50 mg/1OralBayer HealthCare Pharmaceuticals Inc.2008-01-30Not applicableUs
PrecoseTablet50 mg/1OralPhysicians Total Care, Inc.1996-07-122011-06-30Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AcarboseTablet100 mg/1OralStrides Shasun Limited2011-07-28Not applicableUs
AcarboseTablet25 mg/1OralPhysicians Total Care, Inc.2008-10-03Not applicableUs54868 594520180907 15195 zdvxv7
AcarboseTablet100 mg/1OralActavis Pharma Company2008-05-082018-10-22Us
AcarboseTablet100 mg/1OralMayne Pharma2011-07-272017-11-27Us
AcarboseTablet25 mg/1OralAv Kare, Inc.2013-12-24Not applicableUs
AcarboseTablet25 mg/1OralVirtus Pharmaceuticals LLC2015-02-01Not applicableUs
AcarboseTablet100 mg/1OralWest-Ward Pharmaceuticals Corp2008-05-07Not applicableUs
AcarboseTablet50 mg/1OralImpax Generics2009-05-142017-04-30Us00115 1151 01 nlmimage10 7d3abef5
AcarboseTablet50 mg/1Oralbryant ranch prepack2011-07-28Not applicableUs
AcarboseTablet100 mg/1OralAv Kare, Inc.2013-12-24Not applicableUs
International/Other Brands
Prandase (Bayer AG)
Categories
UNII
T58MSI464G
CAS number
56180-94-0
Weight
Average: 645.608
Monoisotopic: 645.248013549
Chemical Formula
C25H43NO18
InChI Key
CEMXHAPUFJOOSV-XGWNLRGSSA-N
InChI
InChI=1S/C25H43NO18/c1-7-13(26-9-2-8(3-27)14(33)18(37)15(9)34)17(36)20(39)24(41-7)44-23-12(6-30)42-25(21(40)19(23)38)43-22(11(32)5-29)16(35)10(31)4-28/h2,4,7,9-27,29-40H,3,5-6H2,1H3/t7-,9+,10+,11-,12-,13-,14-,15+,16-,17+,18+,19-,20-,21-,22-,23-,24-,25-/m1/s1
IUPAC Name
(2R,3R,4R,5R)-4-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3,5,6-tetrahydroxyhexanal
SMILES
[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O

Pharmacology

Indication

For treatment and management of diabetes type II (used in combination therapy as a second or third line agent)

Associated Conditions
Pharmacodynamics

Used to reduce blood gluose in patients with type 2 diabetes. Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. Acarbose binds to and inhibits alpha amylase and alpha-gluocside hydrolases. In diabetic patients, this enzyme inhibition results in a delayed glucose absorption and a lowering of postprandial hyperglycemia.

Mechanism of action

Acarbose reversibly bind to pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolases. These enzymes inhibit hydrolysis of complex starches to oligosaccharides in the lumen of the small intestine and hydrolysis of oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the brush border of the small intestine.

TargetActionsOrganism
AMaltase-glucoamylase, intestinal
inhibitor
Human
APancreatic alpha-amylase
inhibitor
Human
ALysosomal alpha-glucosidase
inhibitor
Human
ASucrase-isomaltase, intestinal
inhibitor
Human
Absorption

Extremely low bioavailability. Less than 2% of an oral dose of acarbose was absorbed as active drug. Peak plasma concentrations of the active drug were achieved 1 hour after dosing. Drug accumulation does not occur with multiple doses.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Acarbose is only metabolized within the gastrointestinal tract by intestinal bacteria and also digestive enzymes to a lesser extent. 4-methylpyrogallol derivatives (sulfate, methyl, and glucuronide conjugates) are the major metabolites. One metabolite (formed by cleavage of a glucose molecule from acarbose) also has alpha-glucosidase inhibitory activity.

Route of elimination

The fraction of acarbose that is absorbed as intact drug is almost completely excreted by the kidneys. A fraction of the metabolites (approximately 34% of the dose) was absorbed and subsequently excreted in the urine. The active metabolite is excreted into the urine and accounts for less than 2% of the total administered dose. When given intravenously, 89% of the dose was excreted into the urine as the active drug. When given orally, less than 2% of the oral dose was recovered into the urine as active (parent compound and active metabolite) drug.

Half life

Healthy volunteers = 2 hours

Clearance
Not Available
Toxicity

Gastrointestinal symptoms are the most common reactions to acarbose.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when Acarbose is combined with 2,4-thiazolidinedione.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Acarbose can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
AbacavirAcarbose may decrease the excretion rate of Abacavir which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcetaminophenAcarbose may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
AcetazolamideThe therapeutic efficacy of Acarbose can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Acarbose can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Acarbose.
Food Interactions
  • Take with food, at beginning of each meal.

References

Synthesis Reference

Anneliese Crueger, Wolfgang Piepersberg, Jurgen Distler, Ansgar Stratmann, "Acarbose biosynthesis genes from actinoplanes sp., process for the isolation thereof and the use thereof." U.S. Patent US5753501, issued December, 1977.

US5753501
General References
  1. Clissold SP, Edwards C: Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1988 Mar;35(3):214-43. [PubMed:3286212]
External Links
KEGG Drug
D00216
KEGG Compound
C06802
PubChem Compound
9811704
PubChem Substance
46508248
ChemSpider
23264314
ChEBI
2376
ChEMBL
CHEMBL1566
Therapeutic Targets Database
DCL000309
PharmGKB
PA448010
HET
QPS
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Acarbose
ATC Codes
A10BF01 — AcarboseA10BD17 — Metformin and acarbose
AHFS Codes
  • 68:20.02 — Alpha-glucosidase Inhibitors
FDA label
Download (268 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingPreventionRetinopathy, Diabetic1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableType 2 Diabetes Mellitus3
1CompletedTreatmentHealthy Volunteers1
2CompletedPreventionAging1
2CompletedTreatmentPostprandial Hypotension / Type 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus1
2RecruitingTreatmentAging1
2RecruitingTreatmentHyperinsulinemic Hypoglycemia1
2RecruitingTreatmentOther Specified Hypotension / Syncope1
2TerminatedTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
3CompletedNot AvailableMetabolic Syndromes1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Pressure (Hypertension) / High Cholesterol / Type 2 Diabetes Mellitus1
3CompletedPreventionCoronary Artery Disease / Glucose Metabolism Disorders1
3CompletedPreventionEndothelial Dysfunction / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Mellitus (DM)1
3CompletedTreatmentSubclinical Inflammation / Type 2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus5
3RecruitingTreatmentGestational Diabetes Mellitus as Antepartum Condition1
3RecruitingTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3Unknown StatusTreatmentPlus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in / Subjects With Type 2 Diabetes Mellitus / The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg1
4Active Not RecruitingPreventionAcute Coronary Syndromes (ACS) / Coronary Heart Disease (CHD) / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
4CompletedTreatmentBMI >30 kg/m2 / General Surgery / Hypoglycemia1
4CompletedTreatmentCardiovascular Risk Factors / Glucose tolerance impaired / Hyperglycemia, Postprandial1
4CompletedTreatmentCoronary Artery Disease / Newly Diagnosed Type 2 Diabetes1
4CompletedTreatmentDiabetes Mellitus (DM)1
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus2
4CompletedTreatmentPCO1
4CompletedTreatmentType 2 Diabetes Mellitus11
4Not Yet RecruitingTreatmentAtherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-11
4Not Yet RecruitingTreatmentImpaired Glucose Tolerance (IGT) / Polycystic Ovarian Syndrome1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
4RecruitingBasic ScienceHealthy Volunteers1
4RecruitingTreatmentAcarbose / Endothelial Function / Gemigliptin / Type 2 Diabetes Mellitus1
4RecruitingTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetes Mellitus3
4TerminatedTreatmentCardiovascular Disease (CVD) / Impaired Glucose Tolerance (IGT) / Insulin Resistance / Pediatric Obesity1
4TerminatedTreatmentType 2 Diabetes Mellitus1
4Unknown StatusBasic ScienceType 2 Diabetes Mellitus1
4Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection1
4Unknown StatusTreatmentCoronary Artery Disease / Diabetes Mellitus (DM) / Impaired Glucose Tolerance (IGT)1
4Unknown StatusTreatmentDiabetes Mellitus (DM)1
Not AvailableActive Not RecruitingBasic SciencePolycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailableDiabetes Mellitus (DM)5
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus6
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingBasic ScienceGlucose Metabolism Disorders1
Not AvailableRecruitingDiagnosticCoronary Artery Disease / Diabetes Mellitus (DM)1
Not AvailableRecruitingTreatmentPolycystic Ovaries Syndrome1
Not AvailableUnknown StatusTreatmentDiabetes Mellitus (DM) / Impaired Glucose Tolerance (IGT)1
Not AvailableWithdrawnNot AvailableType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
  • Impax laboratories inc
  • Roxane laboratories inc
  • Watson laboratories inc
  • Bayer healthcare pharmaceuticals inc
Packagers
  • Arrow Pharm Malta Ltd.
  • A-S Medication Solutions LLC
  • Bayer Healthcare
  • Cobalt Pharmaceuticals Inc.
  • Global Pharmaceuticals
  • Impax Laboratories Inc.
  • Kaiser Foundation Hospital
  • Murfreesboro Pharmaceutical Nursing Supply
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Roxane Labs
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral100 mg
TabletOral50 mg
TabletOral50 mg/1
Prices
Unit descriptionCostUnit
Acarbose 100 100 mg tablet Bottle120.62USD bottle
Acarbose 100 50 mg tablet Bottle100.71USD bottle
Acarbose 100 25 mg tablet Bottle93.54USD bottle
Precose 100 mg tablet1.28USD tablet
Acarbose 100 mg tablet1.17USD tablet
Precose 50 mg tablet1.11USD tablet
Precose 25 mg tablet1.01USD tablet
Acarbose 25 mg tablet0.91USD tablet
Acarbose 50 mg tablet0.88USD tablet
Glucobay 100 mg Tablet0.4USD tablet
Glucobay 50 mg Tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-6.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility108.0 mg/mLALOGPS
logP-2.7ALOGPS
logP-8.3ChemAxon
logS-0.78ALOGPS
pKa (Strongest Acidic)11.83ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area329.01 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity139.02 m3·mol-1ChemAxon
Polarizability62.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8467
Blood Brain Barrier-0.9723
Caco-2 permeable-0.725
P-glycoprotein substrateSubstrate0.5316
P-glycoprotein inhibitor IInhibitor0.5421
P-glycoprotein inhibitor IINon-inhibitor0.8656
Renal organic cation transporterNon-inhibitor0.8647
CYP450 2C9 substrateNon-substrate0.7581
CYP450 2D6 substrateNon-substrate0.8505
CYP450 3A4 substrateNon-substrate0.5683
CYP450 1A2 substrateNon-inhibitor0.8791
CYP450 2C9 inhibitorNon-inhibitor0.8677
CYP450 2D6 inhibitorNon-inhibitor0.8974
CYP450 2C19 inhibitorNon-inhibitor0.8392
CYP450 3A4 inhibitorNon-inhibitor0.986
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7163
Ames testNon AMES toxic0.8054
CarcinogenicityNon-carcinogens0.967
BiodegradationNot ready biodegradable0.6447
Rat acute toxicity1.4610 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8586
hERG inhibition (predictor II)Non-inhibitor0.8288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
Oligosaccharides / Alkyl glycosides / O-glycosyl compounds / Beta-hydroxy aldehydes / Cyclitols and derivatives / Oxanes / Alpha-hydroxyaldehydes / 1,2-aminoalcohols / Secondary alcohols / Polyols
show 7 more
Substituents
Oligosaccharide / Amino cyclitol glycoside / Fatty acyl glycoside / Alkyl glycoside / Glycosyl compound / O-glycosyl compound / Cyclitol or derivatives / Beta-hydroxy aldehyde / Fatty acyl / Oxane
show 20 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Maltose alpha-glucosidase activity
Specific Function
May serve as an alternate pathway for starch digestion when luminal alpha-amylase activity is reduced because of immaturity or malnutrition. May play a unique role in the digestion of malted dietar...
Gene Name
MGAM
Uniprot ID
O43451
Uniprot Name
Maltase-glucoamylase, intestinal
Molecular Weight
209850.8 Da
References
  1. Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM, Boer MA, Takeuchi H, Van Diggelen OP, Reuser AJ: A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab. 2006 May;88(1):22-8. Epub 2005 Dec 15. [PubMed:16359900]
  2. Zhang H, Kallwass H, Young SP, Carr C, Dai J, Kishnani PS, Millington DS, Keutzer J, Chen YT, Bali D: Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med. 2006 May;8(5):302-6. [PubMed:16702880]
  3. Gelb MH, Turecek F, Scott CR, Chamoles NA: Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):397-404. [PubMed:16763908]
  4. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S: Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab. 2009 Feb;10(2):159-63. [PubMed:19275550]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Chloride ion binding
Specific Function
Not Available
Gene Name
AMY2A
Uniprot ID
P04746
Uniprot Name
Pancreatic alpha-amylase
Molecular Weight
57706.51 Da
References
  1. Jonas L, Mikkat U, Lehmann R, Schareck W, Walzel H, Schroder W, Lopp H, Pussa T, Toomik P: Inhibitory effects of human and porcine alpha-amylase on CCK-8-stimulated lipase secretion of isolated rat pancreatic acini. Pancreatology. 2003;3(4):342-8. [PubMed:12890998]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Maltose alpha-glucosidase activity
Specific Function
Essential for the degradation of glygogen to glucose in lysosomes.
Gene Name
GAA
Uniprot ID
P10253
Uniprot Name
Lysosomal alpha-glucosidase
Molecular Weight
105322.935 Da
References
  1. Salehi A, Fan BG, Ekelund M, Nordin G, Lundquist I: TPN-evoked dysfunction of islet lysosomal activity mediates impairment of glucose-stimulated insulin release. Am J Physiol Endocrinol Metab. 2001 Jul;281(1):E171-9. [PubMed:11404235]
  2. Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH: Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem. 2004 Oct;50(10):1785-96. Epub 2004 Aug 3. [PubMed:15292070]
  3. Lundquist I, Panagiotidis G: The relationship of islet amyloglucosidase activity and glucose-induced insulin secretion. Pancreas. 1992;7(3):352-7. [PubMed:1594557]
  4. Zhang H, Kallwass H, Young SP, Carr C, Dai J, Kishnani PS, Millington DS, Keutzer J, Chen YT, Bali D: Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med. 2006 May;8(5):302-6. [PubMed:16702880]
  5. Gelb MH, Turecek F, Scott CR, Chamoles NA: Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):397-404. [PubMed:16763908]
  6. Lullmann-Rauch R, Watermann D: Fusion of storage lysosomes in experimental lipidosis and glycogenosis. Exp Mol Pathol. 1987 Feb;46(1):136-43. [PubMed:3467980]
  7. Bourbon JR, Doucet E, Rieutort M: Role of alpha-glucosidase in fetal lung maturation. Biochim Biophys Acta. 1987 Jan 13;917(1):203-10. [PubMed:3539207]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sucrose alpha-glucosidase activity
Specific Function
Plays an important role in the final stage of carbohydrate digestion. Isomaltase activity is specific for both alpha-1,4- and alpha-1,6-oligosaccharides.
Gene Name
SI
Uniprot ID
P14410
Uniprot Name
Sucrase-isomaltase, intestinal
Molecular Weight
209451.49 Da
References
  1. Juretic D, Bernik S, Cop L, Hadzija M, Petlevski R, Lukac-Bajalo J: Short-term effect of acarbose on specific intestinal disaccharidase activities and hyperglycaemia in CBA diabetic mice. J Anim Physiol Anim Nutr (Berl). 2003 Aug;87(7-8):263-8. [PubMed:12864906]
  2. Meyer H, Wieczorek H, Zeiske W: K+ transport in the caterpillar intestine epithelium: role of osmolytes for the K+-secretory capacity of the tobacco hornworm midgut. J Comp Physiol B. 2004 Oct;174(7):527-39. Epub 2004 Aug 20. [PubMed:15322845]
  3. Karley AJ, Ashford DA, Minto LM, Pritchard J, Douglas AE: The significance of gut sucrase activity for osmoregulation in the pea aphid, Acyrthosiphon pisum. J Insect Physiol. 2005 Dec;51(12):1313-9. Epub 2005 Sep 15. [PubMed:16169004]
  4. Samulitis BK, Goda T, Lee SM, Koldovsky O: Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res. 1987;13(8):517-24. [PubMed:2962844]
  5. Newbrun E, Hoover CI, Walker GJ: Inhibition by acarbose, nojirimycin and 1-deoxynojirimycin of glucosyltransferase produced by oral streptococci. Arch Oral Biol. 1983;28(6):531-6. [PubMed:6226260]

Drug created on June 13, 2005 07:24 / Updated on December 16, 2018 23:30